Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity

Abstract excerpt

The origins of preexisting SARS-CoV-2 cross-reactive antibodies and their potential impacts on vaccine efficacy have not been fully clarified. In this study, we demonstrated that S2 was the prevailing target of the preexisting S protein cross-reactive antibodies in both healthy human and SPF mice. A dominant antibody epitope was identified on the connector domain of S2 (1147-SFKEELDKYFKNHT-1160, P144), which...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to SARS-CoV-2 and COVID-19 Research
• Share to Vaccine Coverage and Hesitancy
• Share to Viral gastroenteritis research and epidemiology